Skip to content
Screener

iRadimed IRMD Q2 2026 earnings

Reported July 31, 2026 · Before market open

Revenue$20.5MBeat by $116.0K
EPS$0.46Beat by $0.02
Revenue estimate$20.4M
EPS estimate$0.44
For the third quarter of 2026, we expect revenue of $23.0 million to $24.5 million and GAAP diluted earnings per share of $0.49 to $0.54 and non-GAAP diluted earnings per share of $0.54 to $0.59. We reaffirm our guidance for the full-year 2026, expecting to report revenue of $91.0 million to $96.0 million, and GAAP diluted earnings per share of $1.90 to $2.05 and non-GAAP diluted earnings per share of $2.09 to $2.24
Roger Susi

Next report

Nov 2, 2026 (in a month)
Revenue estimate$23.2M
EPS estimate$0.52

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.05B+17.3%
P/E44.6×+1.1×
P/S12.2×+0.6×

FAQ

When did iRadimed report Q2 2026 earnings?
iRadimed (IRMD) reported Q2 2026 earnings on July 31, 2026 before market open.
What were iRadimed's Q2 2026 revenue and EPS?
iRadimed reported revenue of $20.5M and eps of $0.46 for Q2 2026.
Did iRadimed beat estimates in Q2 2026?
Revenue beat the consensus estimate of $20.4M by $116.0K. EPS beat the consensus estimate of $0.44 by $0.02.
How did iRadimed's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.3% from $20.4M a year earlier and eps declined 6.1% from $0.49.
Where can I find iRadimed's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-051240) and the 10-Q periodic report (0001628280-26-051402) directly on SEC EDGAR. The filing index links above go to sec.gov.